BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
1. BioAtla presented Phase 1 data for BA3182 targeting metastatic adenocarcinoma. 2. Encouraging tumor reductions observed in 5 patients; safety profile remains reassuring. 3. Ongoing dose escalation of BA3182 shows potential for significantly improved outcomes. 4. Targeting EpCAM may allow BA3182 to serve over one million patients globally. 5. Updated Phase 1 data expected in 2H2025, showcasing ongoing research significance.